Tell the President to Stop Putting COVID-19 Research at Risk

Our government’s number one priority should be to beat COVID-19, including supporting the search for much-needed treatments and vaccines. Unfortunately, the president has signed a new executive order that would threaten the very research we need to rid the United States and the world of this pandemic. The proposal is a dangerous and unnecessary distraction to solving the current pandemic. Tell the president to stop this policy immediately.


Tell the White House: Stop Putting COVID-19 Research at Risk

Lupus patient Addy
Mother of 4 Amy

Tell the White House: Stop Putting COVID-19 Research at Risk

Biopharmaceutical scientists and researchers have been working around the clock to develop new vaccines and medicines to treat and prevent COVID-19, but we aren’t there yet. Despite this, the president has signed an executive order that puts current and future research at risk.


The new proposal would allow the government to set the price of medicines based on foreign governments’ decisions – foreign countries where access to innovative therapies is restricted and investment in treatments and cures is lacking. Case in point, nearly 90% of new medicines launched since 2011 are available in the United States compared to just 50% on average in these other foreign countries. This policy hurts Americans, especially seniors, when we should be helping all Americans stay healthy and get the economy going again. It is a step backwards for the United States when our nation should be doing everything it can to beat COVID-19.


Now more than ever, we need policies that support the development of new medicines, not policies like the latest executive order that will upend medical research and innovation in the United States. Tell President Trump to stop this policy immediately so we can get back to focusing on finding treatments and vaccines for COVID-19.

Our Focus

Voters for Cures

The next medical breakthrough is more than just science. It’s personal. Voters for Cures is a leading voice for patients, their families and the health care professionals who understand what’s at stake if policies do not support patient affordability and access, as well as continued medical innovation. Our efforts focus on three core areas:


Patient Voices, Policy Solutions & Cutting-Edge Research

The following articles share policy solutions, exciting R&D progress, and advocate spotlights where patients and those that care for them share the reasons why they vote for cures.

Sickle cells with green overlay

America's biopharmaceutical companies are researching and developing new treatments to alleviate the tremendous burden of this devastating and painful disease and to improve the quality of life for sickle cell patients.

image of stethoscope

America's biopharmaceutical companies recognize the need for evidence-based research and cross-sector partnerships to address health inequity in communities of color.

Researcher in Lab

From advanced biologics to transformative therapies, such as cell and gene therapy, recent advancements have revolutionized our ability to treat, and in some cases cure, some of the most challenging diseases.